Antibody Collaboration and Licensing Deals 2019-2026

$4,995.00

Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2026

Publication date
May 2026
Number of pages
850+
Product type
Research report
Report edition
9
SKU
CP2113

Request your free report sample

Antibody Collaboration and Licensing Deals

The Antibody Collaboration and Licensing Deals report delivers a comprehensive and commercially focused analysis of global dealmaking across antibody therapeutics - equipping business development teams with the critical intelligence required to compete effectively in one of the most active and high-value areas of biopharma partnering.

Covering deals announced since 2019, the report provides a detailed and structured database of antibody transactions spanning collaborations, licensing agreements, and strategic partnerships across discovery, development, and commercialization.


Report Scope

This report provides a complete and actionable view of the antibody partnering landscape, combining granular deal data with contract-level insight to support confident, evidence-based decision-making.

Coverage includes:

  • Collaboration and licensing deals across antibody therapeutics

  • Detailed financial terms including upfronts, milestones, and royalties

  • Access to underlying contract documents where disclosed

  • Analysis of deal structures across antibody formats, including monoclonal antibodies, bispecifics, and antibody-drug conjugates (ADCs)


Key Features

  • Comprehensive analysis of antibody dealmaking activity and trends since 2019

  • Identification of the most active and strategically relevant dealmakers

  • Robust benchmarking of financial terms across comparable transactions

  • Detailed evaluation of deal structures, including rights allocation and development responsibilities

  • Contract-level insights into key clauses where disclosures are available

  • Focused analysis of ADCs as a rapidly expanding, high-value partnering segment driving deal activity


What This Report Enables You To Do

  • Benchmark antibody and ADC deal terms with confidence

  • Identify and prioritise high-value partnering opportunities

  • Understand how leading companies are structuring competitive deals

  • Validate deal assumptions using real-world transaction data

  • Strengthen negotiation positioning with evidence-backed insights

  • Save hundreds of hours of research time by accessing a fully curated, structured deal and contract dataset in one place

  • Accelerate BD decision-making in a fast-moving and competitive market


Report Structure

The report is organized into the following sections:

  • Overview of antibody dealmaking

  • Trends in antibody partnering activity

  • Analysis of leading deals by value

  • Most active companies in antibody dealmaking

  • Contract analysis and deal structure insights

  • Deal analysis by antibody technology type, including ADCs


Commercial Relevance

Antibody therapeutics remain a core pillar of biopharma dealmaking, with sustained activity across established modalities and accelerating momentum in next-generation formats.

In particular, antibody-drug conjugates (ADCs) have emerged as one of the most competitive and capital-intensive areas of partnering, driving a surge in high-value transactions and strategic collaborations.

In this environment, access to high-quality, deal-level and contract-level intelligence is essential.

This report provides the insight required to benchmark effectively, identify the right partners, and execute deals with greater confidence—ensuring your BD strategy is grounded in how transactions are actually being structured and negotiated in the market today.

Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2019
•    Browse antibody collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in antibody dealmaking
2.1. Introduction
2.2. Antibody deals over the years
2.3. Most active antibody dealmakers
2.4. Antibody deals by deal type
2.5. Antibody deals by therapy area
2.6. Antibody deals by industry sector
2.7. Deal terms for antibody deals
2.7.1 Antibody deals headline values
2.7.2 Antibody deal upfront payments
2.7.3 Antibody deal milestone payments
2.7.4 Antibody royalty rates

Chapter 3 – Leading antibody deals
3.1. Introduction
3.2. Top antibody deals by value

Chapter 4 – Most active antibody dealmakers
4.1. Introduction
4.2. Most active antibody dealmakers
4.3. Most active antibody deals company profiles

Chapter 5 – Antibody contracts dealmaking directory
5.1. Introduction
5.2. Antibody contracts dealmaking directory

Chapter 6 – Antibody dealmaking by technology type

Deal directory

Deal directory – Antibody deals by company A-Z
Deal directory – Antibody deals by deal type
Deal directory – Antibody deals by therapy area

Deal type definitions

About Biopharma Research Ltd    
Current Partnering
Current Agreements
Recent report titles from Current Partnering



Table of figures

Figure 1: Antibody deals since 2019
Figure 2: Active antibody dealmaking activity
Figure 3: Antibody deals by deal type since 2019
Figure 4: Antibody deals by therapy area since 2019
Figure 5: Antibody deals by industry sector since 2019
Figure 6: Antibody deals with a headline value
Figure 7: Antibody deals with an upfront value
Figure 8: Antibody deals with a milestone value
Figure 9: Antibody deals with a royalty rate value
Figure 10: Top antibody deals by value since 2019
Figure 11: Most active antibody dealmakers
Figure 12: Antibody deals by technology type since 2019

Pricing options

  • $4,995: single-user (encrypted file - one user/device)
  • $6,995: multi-user (encrypted file - up to 5 users/devices)
  • $8,995: company (unencrypted PDF)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

 

Sales Support

If you have any questions about your report, we will do our best to resolve your query. Contact us direct.

1ST Biotherapeutics, 3D Medicines, 3rd People’s Hospital of Shenzhen, 3SBio, 4C Biomed, 4D Path, 4D Pharma, 9 Meters Biopharma, 10X Genomics, 23andMe, A*STAR Agency for Science, Technology and Research, A*STAR Bioprocessing Technology Institute, Aadi Bioscience, Aarhus University, Aarvik Therapeutics, Abbvie, Abcam, AbCellera Biologics, AbCheck, Abcuro, Abdul Latif Jameel Health, Abilita Bio, Abilita Therapeutics, ABL Bio, Ablexis, Ablynx, Abound Bio, Aboundbio, Abpro, AbSci, Absolute Antibody, Ab Studio, AbTherx, AbTis, Abveris, Abzena, Accurus Biosciences, AcedrA BioPharmaceuticals, Acepodia, Acerta Pharma, AchilleS Vaccines, Aclaris Therapeutics, Actinium Pharmaceuticals, Active Motif, Actuate Therapeutics, Acumen Pharmaceuticals, Adagene, Adaptate Biotherapeutics, Adaptive Biotechnologies, Adcendo, Adcentrx Therapeutics, ADC Therapeutics, Addgene, ADEL, Adimab, Adlai Nortye, Adnab, Advanced Biological Laboratories, Advanz Pharma, Advaxis, Aegis Life, Aethon Therapeutics, Aevi Genomic Medicine, AffaMed Therapeutics, Affibody, Affinity Biosciences, AGC Biologics, Agenus Bio, Agilent Technologies, AgomAb Therapeutics, AgonOx, AimedBio, AIM ImmunoTech, Aimmune Therapeutics, Ainnocence, Ajinomoto, Akadeum Life Sciences, Akari Therapeutics, Akeso Biopharma, Akston Biosciences, Alamar Biosciences, Alchemab, Alchemab Therapeutics, Alector, Alexion Pharmaceuticals, Alfasigma, AlivaMab Discovery Services, Alkyon Therapeutics, Alligator Bioscience, Allinaire Therapeutic, Alloy Therapeutics, Almac Discovery, Almac Group, Almirall, Alopexx, Alphamab Biopharmaceuticals, Alphamab Oncology, Alpine Immune Sciences, Alteogen, Alvotech, ALX Oncology, Alytas Therapeutics, Alzheimer's Drug Discovery Foundation, ALZpath, Amagma Therapeutics, Ambrx, AmerisourceBergen, Amgen, AmMax Bio, Amneal Pharmaceuticals, Amolyt Pharma, Amplyx Pharmaceuticals, AnaptysBio, Angios, Animal Allergy Clinical Laboratories, Ankyra Therapeutics, Annogen, Antengene, Anthos Therapeutics, Antidote Therapeutics, Antikor Biopharma, Antiverse, Apeiron Biologics, Apexigen, Apollo Therapeutics, Applied BioMath, Applied Biomedical Science Institute, AprilBio, APRINOIA Therapeutics, Aptevo Therapeutics, Araris Biotech, Aravive Biologics, Arch Oncology, Arcus Biosciences, Ardeagen, Arecor Therapeutics, argenx, Aridis Pharmaceuticals, Arizona State University, Arovella Therapeutics, ArriVent Biopharma, ArrowMark Partners, Arsenal Biosciences, Artisan Bio, Artizan Biosciences, Aruvant Sciences, Asahi Kasei, Ascentage Pharma, Ascletis, Asher Biotherapeutics, Asieris MediTech, Aslan Pharma, ASLAN Pharmaceuticals, Astellas Pharma, Astellas Pharma US, AstraZeneca, Astria Therapeutics, Asylia Therapeutics, Asymchem Laboratories, Atlante Biotech, Atlas Antibodies, Atlas Venture, Atonco, Atossa Therapeutics, Atreca, Attralus, ATUM, aTyr Pharma, Augmenta, AusHealth, Avacta, Avalo Therapeutics, AvantGen, Avantor, Avenzo Therapeutics, AVEO Oncology, Avid Bioservices, Avidity Biosciences, Avrobio, Axantia, Baili Biopharmaceutical, Banner Alzheimer's Institute, Basilea Pharmaceutica, Batavia Biosciences, Bausch & Lomb, Bayer, Beam Therapeutics, Beckman Coulter, BeiGene, Beijing Defengrei Biotechnology, Beijing InnoCare Pharma, Beijing Mabworks Biotech, Beijing Tianshi Tongda Pharmaceuticals Technology, BeOne Medicines, Berkeley Lights, Beroni Group, Bethyl Laboratories, Betta Pharmaceuticals, Bielefeld University, BigHat Biosciences, Bill and Melinda Gates Foundation, Binex, Binghamton University, Bio-Manguinhos/Fiocruz, Bio-Techne, Bio-Thera Solutions, BioArctic AB, biOasis Technologies, BioAtla, Biocare Medical, BioCina, BioCity Biopharma, Biocon, Biocytogen, BioDuro, Bioelectronica, Bioeq IP, Biogen, BioGeometry, Biohaven Pharmaceuticals, BioInvent, Biolojic Design, BioMap, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, Biomm, Biomunex Pharmaceuticals, Bioncotech Therapeutics, Biond Biologics, BiondVax, BiOneCure Therapeutics, BioNova Pharmaceuticals, Bionoveo, BioNTech, BiosanaPharma, Biosidus, Biosion, Biositu Pharmaceutical Technology, BioStrand, Biotem, Biotheus, Biotools, BioXcel, BiVictriX Therapeutics, BJ Bioscience, Blackstone, BliNK Biomedical, Bliss Biopharmaceutical, Bluebird Bio, BlueJay Therapeutics, Boehringer Ingelheim, Bolt Biotherapeutics, Boostimmune, BostonGene, Boston Immune Technologies and Therapeutics, Boston Pharmaceuticals, Bpifrance, BriaCell Therapeutics, BrickBio, BridgeBio Pharma, Brigham and Women's Hospital, BrighGene Biomedical, Bright Peak Therapeutics, Brii Biosciences, Bristol-Myers Squibb, Byondis, C-Bridge Capital, C4 Therapeutics, Calico, Califia Pharma, Calixar, Calviri, Calypso Biotech, CanariaBio, Cancer Focus Fund, Cancer Prevention and Research Institute of Texas, Cancer Research UK, Cancer Science Institute of Singapore, CanCure, Candid Therapeutics, Cantargia, Caprisa, CARB-X, Care Access Research, CareDx, Carina Biotech, Caris Life Sciences, CARsgen, Carterra, Cartexell, Cartography Biosciences, CASI Pharmaceuticals, Catalent, CDR-Life, Cedars-Sinai Medical Center, Celdara Medical, Celgene, Celiac Disease Foundation, Cellectis, Cell Signaling Technology, Celltrion, Celsius Therapeutics, Celularity, Cend Therapeutics, Centers for Disease Control and Prevention, Centessa Pharmaceuticals, Centre Leon Berard, Cessation Therapeutics, CG Oncology, Champions Oncology, Charles River Laboratories, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chi-Med, Chiesi Farmaceutici, Children's Hospital Boston, Chime Biologics, China Resources Pharmaceutical Commercial Group International Trading, Chinese Academy of Sciences, Chiome Bioscience, Chipscreen NewWay Biosciences, Chong Kun Dang, Chromotek, Chugai Pharmaceutical, Cidara Therapeutics, Cipla, Circio, City of Hope Comprehensive Cancer Center, Clarity Pharmaceuticals, Climb Bio, Clinical Trial and Consulting Services, Clinica Universidad Navarra, CMAB Biopharma, CM Life Sciences, Coeptis Pharmaceuticals, Coherus Biosciences, Compass Therapeutics, Complix, Compugen, Confo Therapeutics, Context Therapeutics, Convergent Therapeutics, CORAT Therapeutics, Corbus Pharmaceuticals, Corvidia Therapeutics, CounterX Therapeutics, Cradle, Creative Biolabs, Creoptix, Crescendo Biologics, Crescent Biopharma, Cristalia, Cristal Therapeutics, Cromos Pharma, Crown Bioscience, CSL, CSL Behring, CSPC Megalith Biopharmaceutical, CSPC Pharmaceutical Group, CStone Pharmaceuticals, CtM Biotech, CTTQ-Akeso Biomed, Cue Biopharma, Cullinan Oncology, Cullinan Therapeutics, Curative Biotechnology, Cure Duchenne, CureVac, Curia, Curis, Cytea Bio, Cytodyn, CytomX Therapeutics, Cytovation, CYTOVIA Therapeutics, DAAN Biotherapeutics, Daiichi Sankyo, Dana-Farber Cancer Institute, Day One Biopharmaceuticals, DCx Biotherapeutics, Debiopharm, deCODE Genetics, DeepCDR Biologics, Defence Therapeutics, Defense Advanced Research Projects Agency, Defense Health Agency (US), Department of Defence, Department of Defense, Dermapharm, Dermira, Diaprost, DiNonA, DiosCURE Therapeutics, Disc Medicine, DISCO Pharmaceuticals, Distributed Bio, Dong-A ST, DotBio, Dr. Falk Pharma, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Dragon Sail Pharmaceutical, Dren Bio, DualityBio, Dualogics, Duke-NUS Graduate Medical School Singapore, Duke University, Duoning Biotechnology, Dyadic International, DynamiCure Biotechnology, E25Bio, Earendil Labs, eGenesis, Eikon Therapeutics, EirGenix, Eisai, Elanco, Eledon Pharmaceuticals, Elektrofi, Elevar Therapeutics, Elevation Oncology, Elicio Therapeutics, Eli Lilly, Ellipses Pharma, Elpiscience, Elthera, Emergence Therapeutics, Emergent BioSolutions, Empirico, Enable Injections, Endeavor BioMedicines, EnGeneIC, Enlivex, ENPICOM, Entos Pharmaceuticals, Enzene Biosciences, Enzolytics, EpimAb Biotherapeutics, epitoMAP, Epsilogen, EQRx, Equillium, Erasca, Erasmus University Medical Center, Escugen, EsoCap, Essex Bio-Technology, Ethris, Eucure Biopharma, Eureka Therapeutics, European Commission, European Union Regional Development Fund, EUSA Pharma, Evaxion Biotech, Everest Medicines, Eversana, Evitria, Evive Biotechnology, EvolveImmune Therapeutics, Evopoint Biosciences, Evotec, EVQLV, ExCEEd Orphan, Excellmab, Exelixis, Experimental Therapeutics Centre of Singapore, Eyam Vaccines and Immunotherapeutics, F-Star Therapeutics, FairJourney Biologics, Fannin, FatiAbGen, Femtogenix, Fibrogen, Five Prime Therapeutics, Flame Biosciences, Flare Therapeutics, Florida International University, Flow Eighteen38, Fluidigm, FLX Bio, Food and Drug Administration (FDA), Foreseen Biotechnology, Formation Bio, Formosa Pharmaceuticals, Formycon, Fortis Therapeutics, Forty Seven, Fosun Kite Biotechnology, Fosun Pharmaceutical, Foundation Medicine, Foundery Innovations, Francis Crick Institute, French National Blood Service, Fresenius Kabi Pharmaceuticals, Friends of FSH Research, Frontage Clinical Services, Fuji Pharma, Fujirebio Diagnostics, Fundacion Medina, Fusion Pharmaceuticals, FutureGen Biopharm, Galapagos, Galecto, Gates Medical Research Institute, Gator Bio, GC Biopharma, GC Cell, Gedeon Richter, GemPharmatech, Genagon Therapeutics, Genechem, Geneious Biologics, Genentech, GeneQuantum Healthcare, Generation Biotech, Genezen, GenFleet Therapeutics, Genmab, Gennao Bio, Genome and Company, Genprex, Genrix Bio, Gensci, GenScript Biotech, GenScript ProBio, Genuv, Georgetown University, Georgiamune, German Cancer Research Center, Gero, Gigagen, GI Innovation, Gilead Sciences, Ginkgo BioWorks, Glenmark Pharmaceuticals, Glenmark Pharmaceuticals S.A., GlobalBio, Global Virus Network, GlycoNex, Glycotope Biotechnology, GlycoT Therapeutics, Glykos, Glytherix, Goldfinch Bio, Gossamer Bio, GO Therapeutics, Government of Hong Kong, GPCR Therapeutics, Granite Bio, Grid Therapeutics, Grifols, GSK, Guangzhou Fanen Biotechnology, GV20 Therapeutics, Hainan Sinotau Pharmaceutical, Halozyme Therapeutics, Hangzhou Zhongmei Huadong Pharmaceutical, Hanmi Pharmaceutical, HanX Biopharmaceuticals, Harbour Biomed, HBM Alpha Therapeutics, Hebrew University of Jerusalem, Heidelberg Pharma, Hemogenyx, Hengenix Biotech, Henlius Biotech, HiberCell, HIBio, HiFiBio, Highlight Therapeutics, High Line Bio, Hikma Pharmaceuticals, Hillstream BioPharma, Hinge Bio, Hisun BioRay, Hoffmann La Roche, Hong Kong University of Science & Technology, Hookipa Pharma, Hope Medicine, Horizon Discovery, Horizon Therapeutics, Huadong Medicine, Hualan Genetic, Hubrecht Institute, Humanigen, Hummingbird Bioscience, Huyabio International, Hypospray Pharma, HySlink Therapeutics, I-mab, Iambic Therapeutics, iBio, IcanoMAB, Ichnos Glenmark Innovation, Ichnos Sciences, Ichor Medical Systems, Iconic Therapeutics, Icosagen Group, IDBiologics, IDEAYA Biosciences, IGM Biosciences, Igyxos, Iksuda Therapeutics, Ildong Pharmaceutical, ImaginAb, Imbrium Therapeutics, ImCheck Therapeutics, IMIDomics, Immatics Biotechnologies, Immedica, Immix Biopharma, Immorna, ImmPACT Bio, Immune-Onc Therapeutics, ImmuneCyte Life Sciences, Immuneering, ImmuneOncia Therapeutics, ImmuneOnco Biopharmaceuticals, ImmuNext, Immunitas Therapeutics, ImmunityBio, ImmunoBiochem, Immunocore, ImmunoGen, ImmunoGenesis, Immunome, Immunomedics, ImmunoPrecise Antibodies, ImmunoQure, Immutep, Imugene, IMV, Incyte, Indaptus Therapeutics, Indiana University, Indian Institute of Science Education and Research, Indivumed, InduPro Therapeutics, Infex Therapeutics, Infinimmune, InflamaCORE, InflaRx, Inhalon Biopharma, Inhibrx, Initium Therapeutics, Inmagene Biopharmaceuticals, Innate Pharma, Innolake Biopharm, Innosuisse, Innovate UK, Innovent Biologics, Inotrem, Inovio, Insilico Medicine, InSilicoTrials, Insitro, Inspirna, Instil Bio, Institut Bergonie, Institut Curie, Institute for Basic Science, Institute for Protein Innovation, Institute of Cancer Research, Institut Gustave Roussy, Institut Pasteur, Intarcia Therapeutics, Intas Pharmaceuticals, Integral Molecular, Integrated BioTherapeutics, Intellia Therapeutics, INTELLiSTEM, Intensity Therapeutics, IntoCell, Intract Pharma, Invenra, Invetx, InxMed, IO Biotech, iOnctura, Ionova, IONTAS, Iovance Biotherapeutics, iProgen Biotech, Ipsen, IRBM, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Italian Association for the Study of Pancreas, iTeos Therapeutics, Ixaka, Ix Therapeutics, Jacobio Pharmaceuticals, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Janux Therapeutics, Jasper Therapeutics, Jazz Pharmaceuticals, JCR Pharmaceuticals, Jemincare, Jiangsu Alphamab, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Jiangsu QYuns Therapeutics, JMT-Bio, Johnson & Johnson, Johnson & Johnson Innovation, Jounce Therapeutics, Junshi Biosciences, Juri Biosciences, Just Biotherapeutics, Juvenile Diabetes Research Foundation, JW Therapeutics, KAHR Medical, Kaigene, Kaken Pharmaceutical, Kalbe Genexine Biologics, Kali Therapeutics, KaliVir Immunotherapeutics, KangaBio, Karolinska Institute, Kashiv BioSciences, KBI BioPharma, KBio, KdT Ventures, Kelun-Biotech Biopharmaceutical, Kennedy Institute of Rheumatology, Keymed Biosciences, Kiadis Pharma, Kindred Bio, Kineta, Kings College London, Kiniksa Pharmaceuticals, Kintor, Kissei Pharmaceutical, Kite Pharma, Kleo Pharmaceuticals, Kling Biotherapeutics, Kodiak Sciences, KPM Tech, Kurma Life Sciences Partners, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kyowa Hakko Kirin Pharmaceuticals, kyron.bio, Kyttaro, LabGenius, LabGenius Therapeutics, Laekna, La Jolla Institute for Allergy & Immunology, LamKap Bio Group, LaNova Medicines, Lantern Pharma, Lantheus Holding, Lassen Therapeutics, Lava Therapeutics, Leap Therapeutics, Lee Moffitt Cancer Center, LegoChem Biosciences, Leinco Technologies, LenioBio, LEO Pharma, Lepu Biopharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LeukoCom, Leveragen, Libera Bio, LiberoThera, LifeMax Laboratories, LigaChem Biosciences, Ligand Pharmaceuticals, Light Chain Bioscience, LimmaTech Biologics, Lindis Biotech, Link Cell Therapies, Linnaeus Therapeutics, Lisata Therapeutics, Liverpool School of Tropical Medicine, Livzon Mabpharm, Lobesity Pharma, Lonza, LOTTE Biologics, Loxo Oncology, LTZ Therapeutics, Lunaphore, Lundbeck, Lung Cancer Research Foundation, Lunit, Lupin, Lupus Therapeutics, Lyvgen Biopharma, MabCare Therapeutics, MAB Discovery, Mablink Bioscience, MAbSilico, mAbsolve, Mabwell Bioscience, mAbXience, Mabylon, Macrogenics, Macrostruct Holding & Consulting, Magenta Therapeutics, MAIA Biotechnology, mAIbe, Makana Therapeutics, Mammoth Biosciences, Manhattan BioSolutions, Mapp Biopharmaceutical, Marengo Therapeutics, Massachusetts General Hospital, Massachusetts Institute of Technology, Matrix Medical Network, Max-Delbruck Center for Molecular Medicine, Max-Planck, Maxion Therapeutics, Mayo Clinic, McLean Hospital, McMaster University, McQuade Center for Strategic Research and Development, MD Anderson Cancer Center, Medac, Mediar Therapeutics, Medical Research Council, Medical Research Futures Fund, Medicenna Therapeutics, Medicines Discovery Catapult, Medicovestor, MediGene, MediLink Therapeutics, Medimabs, Medison Pharma, Medivir, MedPacto, Meiji Seika, Memorial Sloan Kettering Cancer Center, Memo Therapeutics, Merck and Co, Merck Animal Health, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Mersana Therapeutics, Merus, Mestag Therapeutics, Metsera, Michael J Fox Foundation, Microbiotica, MilliporeSigma, Minghui Pharmaceutical, miRagen Therapeutics, miRecule, Mirror Biologics, Mitsubishi Tanabe Pharma, Moderna, ModeX Therapeutics, Molcure, Monod Bio, Monopar Therapeutics, MoonLake Immunotherapeutics, Moonlight Bio, MorphoSys, Mount Sinai Health System, Mount Sinai Medical Center, MSD, MS Pharma, MultiOmic Health, Multitude Therapeutics, Mundipharma, Mustang Bio, Mymee, Myricx Bio, Mythic Therapeutics, myTomorrows, Nagoya University Graduate School of Medicine, Nanjing Leads Biolabs, Nanocarry Therapeutics, NanoCellect Biomedica, NanoMab Technology, NaNotics, Nantes University, Nascent Biotech, National Cancer Institute, National Comprehensive Cancer Network (NCCN), National Heart, Lung and Blood Institute, National Institute for Bioprocessing Research and Training, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Standards and Technology, National Institute on Drug Abuse (NIDA), National Institutes of Biomedical Innovation, Health and Nutrition, National Institutes of Health, National Research Council Canada, National University Cancer Institute, Nautilus Biotech, Navigo Proteins, Navrogen, NAYA Biosciences, NBE Therapeutics, nCage Therapeutics, Nectin Therapeutics, Nektar Therapeutics, Nelum Pharma, NeoImmuneTech, Neoleukin Therapeutics, Neotope, NeoX Biotech, Nerviano Medical Sciences, NETRIS Pharma, Neuramedy, Neuraxpharm, Neurimmune Therapeutics, Neurocrine Biosciences, Neximmune, NextCure, NEXT Oncology, NGM Biopharmaceuticals, NiKang Therapeutics, Nippon Kayaku, Nipro Corporation, NJ Bio, NJCTTQ, Nkarta Therapeutics, NKGen Biotech, NKMax America, NMI Natural and Medical Sciences Institute, Nobelpharma, Noetik, Nona Biosciences, Nordic Society of Gynaecological Oncology, Norgine, Normunity, Northern Biologics, NorthStar Medical Radioisotopes, Northway Biotechpharma, Nouscom, NovalGen, NovaRock Biotherapeutics, Novartis, Novatim Immune Therapeutics, Novelty Nobility, NovoCodex, Novocure, Novogene, Novo Nordisk, Noxopharm, NuclixBio, Numab, Nurix Therapeutics, Nxera Pharma, Nykode Therapeutics, OBI Pharma, Oblique Therapeutics, OcellO, Oculis, Odeon Therapeutics, Olatec Therapeutics, Olivia Newton-John Cancer Research Institute, OliX Pharmaceuticals, Ollin Biosciences, Ology Bioservices, Omeros, OmniAb, Ona Therapeutics, OncoC4, Oncologie, Oncolytics Biotech, OncoResponse, OncoSec Medical, OncoVent, OncoVerity, Oncternal Therapeutics, OnCusp Therapeutics, OncXerna Therapeutics, ONK Therapeutics, Ono Pharmaceutical, Onward Therapeutics, OpenEye Scientific Software, Optimeos Life Sciences, Oragenics, Orano Med, Ordaos Bio, ORIC Pharmaceuticals, Orient EuroPharma, Orion, Orum Therapeutics, OSE Immunotherapeutics, Ossianix, Otsuka, Ottimo Pharma, Ouro Medicines, Outlook Therapeutics, Ovensa, Overland ADCT BioPharma, Overland Pharmaceuticals, Oxford BioTherapeutics, Palisade Bio, Palleon Pharmaceuticals, Pandion Therapeutics, Pangu BioPharma, Paragon Therapeutics, Parexel, Parexel Biotech, Parthenon Therapeutics, Partner Therapeutics, Pascal Biosciences, Peptron, Percheron Therapeutics, Personal Genome Diagnostics, Personalis, Pfizer, Phanes Therapeutics, PharmAbcine, PharmaEssentia, Pharmanovia, Pharmapark, Pharmsynthez, PhaseBio Pharmaceuticals, Phenomic AI, Pheon Therapeutics, pH Pharma, Phrontline Biopharma, Pieris Pharmaceuticals, Pierre Fabre, PineTree Therapeutics, Pionyr Immunotherapeutics, Piramal, PlantForm, PlantPraxis Biotecnologia, PMV Pharma, Pneuma Respiratory, POINT Biopharma, Polpharma, Polpharma Biologics, PolyPid, Portage Biotech, Porton Pharma Solutions, PostEra, Precision BioSciences, Prellis Biologics, Prelude Therapeutics, Presage Biosciences, Pressure BioSciences, Prestige BioPharma, ProBioGen, Procarta Biosystems, ProfoundBio, Progenetics, Prokaryotics, Prolium Bioscience, Promega, Prometheus Biosciences, Propeller Bio, ProteinTech, Protelica, Proteona, Prothena, Provention Bio, PT Etana Biotechnologies, Purdue University, Pure Biologics, PureTech Health, Pyramid Biosciences, Pyxis Oncology, Q32 Bio, QBiotics, QIAGEN, Qilu Pharmaceutical, Qinotto, Quadira Biosciences, Quanterix, Quantum Leap Health Care Collaborative, Queensland Institute of Medical Research (QIMR), Quell Therapeutics, Qurient, R-Pharm, Radiance Biopharma, Radiopharm Theranostics, Rakuten Medical, Rallybio, Rani Therapeutics, Rapid Novor, RAPT Therapeutics, Redwood Bioscience, RefleXion Medical, Regeneron Pharmaceuticals, Regenxbio, Regnum, Releviate Therapeutics, REMD Biotherapeutics, RemeGen, Renato Dulbecco Foundation, RenBio, Rentschler Biotechnologie, Repare Therapeutics, Repligen, Resonant Therapeutics, Retrogenix, Reveal Genomics, Revelar Biotherapeutics, Revitope Oncology, Revolution Medicines, RNAGene, Roche, Rockefeller University, Rocket Pharmaceuticals, Rondo Therapeutics, Roswell Park Cancer Institute, Royalty Pharma, RQ Biotechnology, RTW Investments, RubrYc Therapeutics, Rxilient Biotech, Ryvu Therapeutics, Rznomics, SAB Biotherapeutics, Saccharo, Saga University, Sairopa, Salipro Biotech, Samsung Bioepis, Samsung Biologics, Samyang Biopharmaceuticals, San Diego Biomedical Research Institute, Sandoz, Sanofi, Sanofi US Services, Sanyou Biopharmaceuticals, Sarah Cannon Research Institute, Sartorius Stedim Biotech, SATT Conectus Alsace, SaudiVax, Scancell, Scandion Oncology, Scholar Rock, Schrodinger, SciClone Pharmaceuticals, SciCrunch, SciNeuro Pharmaceuticals, Scripps Research Institute, Seagen, Seattle Childrens Research Institute, Seattle Genetics, Secarna Pharmaceuticals, Seismic Bio, Seismic Therapeutic, Selagine, Selecxine, Selexis, Sema4, Sengenics, Sensei Biotherapeutics, SERB Pharmaceuticals, SerImmune, Sernova, Serum Institute of India, Seven and Eight Biopharmaceuticals, SevenScore Pharmaceuticals, SFJ Pharmaceuticals, Shandong Fontacea Pharmaceutical, Shanghai Affinity Biopharmaceutical, Shanghai Medicilon, Shanghai Miracogen, Shanghai ZhenGe Biotechnology, Sharp HealthCare, Shenogen Pharma, Shenzhen Chipscreen Biosciences, Shionogi, SHL Medical, Sidewinder Therapeutics, Siemens Healthineers, SIGA Technologies, Simcere Pharmaceuticals, Simcere Zaiming, Simcha Therapeutics, Simtra BioPharma Solutions, Single Cell Technology, Singlomics Biopharmaceuticals, Sino Biological, Sinorda Biomedicine, Sirnaomics, Siteman Cancer Center, SK Bioscience, Skye Bioscience, Skysong Innovations, SmartPharm Therapeutics, Solstice Oncology, Solve Therapeutics, SomaLogic, Sonnet BioTherapeutics, Sony, Sorrento Therapeutics, Sosei Heptares, SOTIO, Spanish National Research Council, SparX Biopharmaceutical, Specialised Therapeutics, Specifica, Sphere Fluidics, SpikImm, SpringWorks Therapeutics, STADA Arzneimittel, Staidson (Beijing) BioPharmaceuticals, StarkAge Therapeutics, Starpharma, STC Biologics, STCube, Steinbeis Centre for Biopolymer Analysis and Biomedical Mass Spectrometry, Storm Therapeutics, Strata Oncology, Sud Investments, Summit Therapeutics, SunRock Biopharma, Surface Oncology, Surrozen, Sutro Biopharma, Suzhou Connect Biopharmaceuticals, Swedish Orphan Biovitrum, Swiss Rockets, Symphogen, Synaffix, Syndax Pharmaceuticals, Syndivia, Syngene International, Synimmune, Synlogic, Synthekine, Syracuse Biopharma, Syracuse University, Syros Pharmaceuticals, Systimmune, T-Cure Bioscience, Tachyon Therapeutics, Tahoe Therapeutics, Taiho, TaiMed, Taisho Pharmaceutical, Takeda Pharmaceutical, Talem Therapeutics, Tallac Therapeutics, Tanabe Research Laboratories, Targovax, Tasly Pharmaceuticals, Tavotek Biotherapeutics, TCGFB, TCG Labs Soleil, TCR2 Therapeutics, Technical University of Denmark (DTU), Tegmine Therapeutics, Telcon RF Pharmaceuticals, Telix Pharmaceuticals, Tempest Therapeutics, Tempus, TeneoBio, TeneoOne, Teon Therapeutics, Tesaro, Tessa Therapeutics, Tetragenetics, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, TFF Pharmaceuticals, TG Therapeutics, Tharimmune, The International AIDS Vaccine Initiative, The Jackson Laboratory, Theragen, Theramex, Therapharm, Theratechnologies, Thermo Fisher Scientific, Third Arc Bio, Thomas Jefferson University, Tianjin University, TILT Biotherapeutics, Tiziana Life Sciences, Tizona Therapeutics, TJ Biopharma, TNAX Biopharma, TONIX Pharmaceuticals, Toregem BioPharma, Torque Therapeutics, Totient, Touchlight, TRACON Pharmaceuticals, Transcenta, TransThera, Traverse Biosciences, TrialSpark, Trianni, TRIGR Therapeutics, Trinomab Biotech, Trio Pharmaceuticals, Triumvira Immunologics, TrueBinding, TSB Therapeutics, Tsinghua University, Tubulis, TuHURA Biopharma, TuHURA Biosciences, Turgut Ilaclari, Turning Point Therapeutics, Twist Bioscience, UbiVac, Ubix Therapeutics, UCB, Ultragenyx Pharmaceuticals, Uman Diagnostics, UMass Memorial Medical Center, Umoja Biopharma, Undisclosed Company, UnitedHealth, University Gottingen, University Hospital Bonn, University Hospital Heidelberg, University of Alabama at Birmingham, University of Basel, University of Birmingham, University of Bonn, University of British Columbia, University of California Los Angeles, University of California Riverside, University of California San Francisco, University of Florida, University of Georgia, University of Kansas, University of Maryland School of Medicine, University of Minnesota, University of Oxford, University of Pennsylvania, University of Southampton, University of Tubingen, University of Washington, University of Zurich, Upadia, UroGen Pharma, US Army Medical Research and Material Command, US Army Medical Research Institute of Infectious Diseases, Utrecht University, Vaccinex, ValenzaBio, Vanda Pharmaceuticals, Vanderbilt University, VBI Vaccines, Vcell Healthcare, Vect-Horus, VectorY Therapeutics, Velabs Therapeutics, VelaVigo, Veloxis Pharmaceuticals, Vera Therapeutics, Veraxa Biotech, Verily, Verseau Therapeutics, Vertex Pharmaceuticals, Vetigenics, Vetter, VIB, Viela Bio, Vignette Bio, Viking Global Investors, Vincera Pharma, ViralClear Pharmaceuticals, Vir Biotechnology, Viridian Therapeutics, Viroclinics Biosciences, Visterra, Vor Biopharma, Voyager Therapeutics, Vyera Pharmaceuticals, VyGen-Bio, Wacker Biotech, Walgreens, Washington University in St Louis, Waterstone Pharmaceutical, Wellmarker Bio, Werewolf Therapeutics, Wheeler Bio, Whitehawk Therapeutics, WindMIL Therapeutics, Windward Bio, Wisconsin Alumni Research Foundation, Wistar Institute, WuXi Biologics, Wuxi Shuangliang Biotechnology, Wuxi STA, WuXi XDC, Xbrane Biopharma, xCella Biosciences, Xcellon Biologics, Xencor, XERIS Pharmaceuticals, Xiamen Biotime Biotechnology, Xilio Therapeutics, XNK Therapeutics, Xoma, XtalPi, Xuanzhu Biopharma, Xyphos Biosciences, Y-Biologics, Y-mAbs Therapeutics, Yale University, Yarrow Bioscience, Yas Holding, Yissum Research Development, Ymmunobio, Yufan Biotechnologies, YUMAB, ZabBio, Zag Bio, Zai Lab, ZAI Laboratory, Zelgen, Zenas BioPharma, Zentalis Pharmaceuticals, Zentiva, Zenyaku Kogyo, Zoetis, Zumutor Biologics, Zura Bio, Zydus Cadila, Zydus Lifesciences, Zymedi, Zymeworks, ZyVersa Therapeutics

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.


Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.


Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

  • Company press releases and announcements
  • SEC filings and equivalent regulatory disclosures
  • Company and investor presentations
  • Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.


Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

  • Licensing and co-development
  • Research and collaborative R&D
  • Manufacturing, supply, and distribution
  • Commercialisation and co-promotion
  • Equity investments, joint ventures, and asset transactions
  • Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.


Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

  • Financial terms — including upfront payments, milestones, and royalties
  • Rights allocation — development, manufacturing, and commercialization responsibilities
  • Deal structure — exclusivity, territorial scope, and agreement type
  • Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

  • Therapy area and technology type
  • Stage of development
  • Asset type and deal components
  • Geographic scope and exclusivity
  • Source documentation, including press releases and SEC filings

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.


Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

  • How financial mechanisms are defined and triggered
  • How responsibilities are operationalised between parties
  • How flexibility, risk, and control are allocated within agreements

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

  • Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
  • Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
  • Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

  • Benchmarking comparable transactions
  • Supporting valuation and deal structuring
  • Preparing for negotiations
  • Evaluating potential partners
  • Informing internal strategy with real-world evidence

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.